      No vials for sale·Just the research·20 compounds catalogued·10 guides·Updated monthly·
      No vials for sale·Just the research·20 compounds catalogued·10 guides·Updated monthly·
    

          Independent field guide · Est. 2024
        

Most peptides have almost no human data.

Twenty compounds, read end to end: what each one actually is, what the research found, and the part the product page leaves out.

Browse the catalogue How we rate evidence

          Free, no signup|No vials sold|Updated monthly
        

          Most readNo. 01
        

RETA 12 MG

Metabolic & weight

retatrutide

Triple incretin agonist

EvidenceModerate · tier 3

Human trials1 phase 2

Route studiedSubcutaneous

The most talked-about unapproved peptide in the world, on the strength of one mid-stage trial and very little else.

Read the write-up →

Compounds covered

Preclinical only

148

Sources cited

Vials sold, ever

The catalogue

Every compound, rated

{{ shownCount }} showing

{{ c.category }}

{{ c.formula }}

Read the write-up → {{ c.readTime }}

At a glance

The full index

Sorted by strength of human evidence, not by popularity.

      #CompoundClassCategoryEvidenceRoute
    

The scale

Five tiers, applied the same way every time

Ratings describe the evidence, never the hype — and they are route-specific. A topical result never earns an injection rating.

Extensive

Multiple phase 3 trials and an approved label. Two compounds qualify.

Substantial

Approved, but for a narrow population most buyers don't belong to.

Moderate

Real human data, but small trials, short follow-up, or one route only.

Limited

Thin or vendor-adjacent studies that wouldn't survive replication.

Preclinical

Animals or cells only — no completed human trial. Nine of twenty land here.

Before you buy anything

The guides

All ten guides →

01 Reading a certificate of analysis Purity, identity and quantity are three separate tests. 6 min 02 “Research use only” is a category, not a grade Three words doing enormous legal work and no quality work at all. 5 min 03 What FDA Category 2 actually means In 2023 the most popular peptides landed on a list few buyers know about. 5 min 04 Lyophilised powder doesn't last forever Freeze-dried peptide is remarkably stable — reconstituted, it isn’t. 6 min 05 Half the catalogue isn't peptides NAD+, methylene blue and a rotating cast show up for one reason. 4 min 06 Route is not a detail A topical result cannot support an injection. This is the most common overstatement. 6 min 07 Where internet doses come from Trace a popular protocol back far enough and it usually ends at a mouse. 7 min 08 How to read a peptide study Six questions that separate a real result from a citation worth ignoring. 7 min 09 Compounded, prescribed, or grey market Three supply routes, three very different answers to who is accountable. 6 min 10 Banned in sport, legal to own, illegal to sell Three separate legal questions, usually collapsed into one by the seller. 6 min

Editorial method

Four rules, no exceptions

Read the full method →

01

Sources, in order

Regulatory filings and approved labels first, then registered trials with published results, then peer-reviewed literature. Vendor materials are never a source.

02

Route counts

Evidence for one route of administration does not carry to another. A compound with topical human data is described on those terms, never credited for injection.

03

How we're funded

Some links here earn a commission when you buy through them. That never affects a compound's evidence rating or a single word of what we write about it.

04

Corrections in public

When we get something wrong we fix it with a dated note on the page, rather than quietly editing the text and moving on.

The Solanatide brief

One email a month, worth opening

New write-ups, rewritten explainers, and the occasional correction — for people who want the mechanism, not the marketing.

Roughly monthly · one-click unsubscribe